MarcGregoryGhanyMD

Gastroenterology • Bethesda, MD

Hepatology & Liver Transplantation

Physician

Join to view full profile

Are you Dr. Ghany?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 53 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
10 Rockville Pike
Bldg 10
Bethesda, MD 20892
Phone+1 301-402-5115

Fax+1 301-402-0491

Summary

Dr. Marc Ghany, MD is a gastroenterologist in Bethesda, Maryland. He is currently licensed to practice medicine in Louisiana.

Education & Training

Tulane UniversityFellowship, Gastroenterology, 1992 - 1995
Yale-New Haven Medical CenterResidency, Internal Medicine, 1989 - 1992
Royal College of Surgeons IrelandClass of 1989

Certifications & Licensure

LA State Medical License 1992 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Clinical Trials

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Start of enrollment: 2000 Jun 01
Completed
Phase 3
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B Start of enrollment: 2007 Aug 29
Terminated
Phase 2
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1 Start of enrollment: 2008 Aug 01
Completed
Phase 2
Long-term Follow-up of HALT-C Sustained Virological Responders Start of enrollment: 2009 Jan 15
Completed
Duration of Long-term Immunity After Hepatitis B Virus Immunization Start of enrollment: 2010 Sep 08
Completed
Hepatitis B Research Network Adult Cohort Study Start of enrollment: 2010 Dec 01
Completed
Observational Study of Persons With Hepatitis B Virus Infection in North America (Cohort Study) Start of enrollment: 2011 Feb 01
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B Start of enrollment: 2012 May 01
Terminated
Phase 3
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B Start of enrollment: 2012 Nov 01
Completed
Phase 3
Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B Start of enrollment: 2011 May 18
Completed
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir DF Versus Tenofovir DF Monotherapy in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Start of enrollment: 2013 Mar 01
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C Start of enrollment: 2013 May 01
Completed
Phase 2
HBV-HIV Coinfection Research Network Start of enrollment: 2014 Apr 01
Completed
Seroprevalence of Hepatitis E in People With an Organ Transplant Start of enrollment: 2014 Jul 12
Completed
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents Start of enrollment: 2018 Oct 19
Active, not recruiting
Phase 4
Join now to see all

Publications & Presentations

PubMed

Reply: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB.
Marc G Ghany, Wendy C King, Amanda S Hinerman, Anna S F Lok, Mauricio Lisker-Melman
Hepatology. 2024-11-01
HBV RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal.
Norah A Terrault, Richard Sterling, Anna S Lok, Marc G Ghany, Jordan J Feld
The Journal of Infectious Diseases. 2024-10-30
Reply to: "Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies".
Marc G Ghany, Maria Buti, Pietro Lampertico, Hannah M Lee
Journal of Hepatology. 2024-07-01

Press Mentions

FDA Keeps Brand-Name Drugs on a Fast Path to Market ― Despite Manufacturing ConcernsJanuary 23rd, 2020
What’s New in Hepatitis C: Four Themes That Dominated at the Liver MeetingNovember 22nd, 2019
Hepatitis B Debrief: Key Themes That Emerged at AASLDNovember 19th, 2019
Join now to see all

Grant Support

Natural History, Therapy And Pathogenesis Of Chronic Viral Hepatitis CNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
Natural History, Therapy And Pathogenesis Of Chronic Viral Hepatitis BNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
Natural History, Therapy And Pathogenesis Of Chronic Viral Hepatitis CNational Institute Of Diabetes And Digestive And Kidney Diseases2008
Natural History, Therapy And Pathogenesis Of Chronic Viral Hepatitis BNational Institute Of Diabetes And Digestive And Kidney Diseases2008